Advanced Tumor Electric Fields Therapy: A Review of Innovative Research and Development and Prospect of Application in Glioblastoma

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2024 May 8

PMID 38715344

Authors

Jinxin Lan

Yuyang Liu

Junyi Chen

Hongyu Liu

Yaping Feng

Jialin Liu

Ling Chen

Affiliations

Soon will be listed here.

Abstract

Background: Glioblastoma multiforme (GBM) is an aggressive malignant tumor with a high mortality rate and is the most prevalent primary intracranial tumor that remains incurable. The current standard treatment, which involves surgery along with concurrent radiotherapy and chemotherapy, only yields a survival time of 14-16 months. However, the introduction of tumor electric fields therapy (TEFT) has provided a glimmer of hope for patients with newly diagnosed and recurrent GBM, as it has been shown to extend the median survival time to 20 months. The combination of TEFT and other advanced therapies is a promising trend in the field of GBM, facilitated by advancements in medical technology.

Aims: In this review, we provide a concise overview of the mechanism and efficacy of TEFT. In addition, we mainly discussed the innovation of TEFT and our proposed blueprint for TEFT implementation.

Conclusion: Tumor electric fields therapy is an effective and highly promising treatment modality for GBM. The full therapeutic potential of TEFT can be exploited by combined with other innovative technologies and treatments.

Citing Articles

Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma.

Chen J, Liu Y, Lan J, Liu H, Tang Q, Li Z CNS Neurosci Ther. 2024; 30(6):e14802.

PMID: 38887185 PMC: 11183175. DOI: 10.1111/cns.14802.

Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma.

Lan J, Liu Y, Chen J, Liu H, Feng Y, Liu J CNS Neurosci Ther. 2024; 30(5):e14720.

PMID: 38715344 PMC: 11077002. DOI: 10.1111/cns.14720.

References

Mistry A, Dewan M, White-Dzuro G, Brinson P, Weaver K, Thompson R . Decreased survival in glioblastomas is specific to contact with the ventricular-subventricular zone, not subgranular zone or corpus callosum. J Neurooncol. 2017; 132(2):341-349. PMC: 5771712. DOI: 10.1007/s11060-017-2374-3. View

Postiglione I, Chiaviello A, Aloj S, Palumbo G . 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy. Cell Prolif. 2013; 46(4):382-95. PMC: 6622218. DOI: 10.1111/cpr.12040. View

Sottoriva A, Spiteri I, Piccirillo S, Touloumis A, Collins V, Marioni J . Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013; 110(10):4009-14. PMC: 3593922. DOI: 10.1073/pnas.1219747110. View

Pang L, Khan F, Heimberger A, Chen P . Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer. 2022; 8(10):839-854. PMC: 9492629. DOI: 10.1016/j.trecan.2022.04.010. View

Jha P, Manjunath N, Singh J, Mani K, Garg A, Kaur K . Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. Neuropathology. 2019; 39(6):413-424. DOI: 10.1111/neup.12594. View

Du X, Chen C, Xiao Y, Cui Y, Yang L, Li X . Research on application of tumor treating fields in glioblastoma: A bibliometric and visual analysis. Front Oncol. 2022; 12:1055366. PMC: 9684468. DOI: 10.3389/fonc.2022.1055366. View

Toms S, Kim C, Nicholas G, Ram Z . Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol. 2018; 141(2):467-473. PMC: 6342854. DOI: 10.1007/s11060-018-03057-z. View

Kwan K, Schneider J, Patel N, Boockvar J . Tracing the Origin of Glioblastoma: Subventricular Zone Neural Stem Cells. Neurosurgery. 2018; 84(1):E15-E16. DOI: 10.1093/neuros/nyy512. View

Sonabend A, Gould A, Amidei C, Ward R, Schmidt K, Zhang D . Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 2023; 24(5):509-522. PMC: 10256454. DOI: 10.1016/S1470-2045(23)00112-2. View

10.

Bota D, Taylor T, Piccioni D, Duma C, LaRocca R, Kesari S . Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. J Exp Clin Cancer Res. 2022; 41(1):344. PMC: 9749349. DOI: 10.1186/s13046-022-02552-6. View

11.

Park J, Song K, Jung S, Ahn J, Hwang S, Kim J . Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK-κB/MAPK Signaling Pathways. Technol Cancer Res Treat. 2019; 18:1533033819868225. PMC: 6691660. DOI: 10.1177/1533033819868225. View

12.

Wu H, Wang C, Liu J, Zhou D, Chen D, Liu Z . Evaluation of a tumor electric field treatment system in a rat model of glioma. CNS Neurosci Ther. 2020; 26(11):1168-1177. PMC: 7564191. DOI: 10.1111/cns.13441. View

13.

Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X . Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study. CNS Neurosci Ther. 2021; 27(12):1587-1604. PMC: 8611775. DOI: 10.1111/cns.13750. View

14.

He L, Pi Y, Li Y, Wu Y, Jiang J, Rong X . Efficacy and Safety of Apatinib for Radiation-induced Brain Injury Among Patients With Head and Neck Cancer: An Open-Label, Single-Arm, Phase 2 Study. Int J Radiat Oncol Biol Phys. 2022; 113(4):796-804. DOI: 10.1016/j.ijrobp.2022.03.027. View

15.

Rauch P, Park H, Knisely J, Chiang V, Vortmeyer A . Delayed radiation-induced vasculitic leukoencephalopathy. Int J Radiat Oncol Biol Phys. 2011; 83(1):369-75. DOI: 10.1016/j.ijrobp.2011.06.1982. View

16.

Gordon S, Maute R, Dulken B, Hutter G, George B, McCracken M . PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495-499. PMC: 5931375. DOI: 10.1038/nature22396. View

17.

Kirson E, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman R . Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009; 26(7):633-40. PMC: 2776150. DOI: 10.1007/s10585-009-9262-y. View

18.

Gera N, Yang A, Holtzman T, Lee S, Wong E, Swanson K . Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015; 10(5):e0125269. PMC: 4444126. DOI: 10.1371/journal.pone.0125269. View

19.

Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G . Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006; 13(7):1238-41. DOI: 10.1038/sj.cdd.4401872. View

20.

Lan J, Liu Y, Chen J, Liu H, Feng Y, Liu J . Advanced tumor electric fields therapy: A review of innovative research and development and prospect of application in glioblastoma. CNS Neurosci Ther. 2024; 30(5):e14720. PMC: 11077002. DOI: 10.1111/cns.14720. View